Pharmacokinetics and pharmacodynamics of levodopa

被引:114
作者
Nutt, John G. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Neurol, Parkinson Dis Res Educ & Clin Ctr, Portland Va, OR 97239 USA
关键词
levodopa; short-duration response; motor fluctuations; dyskinesia;
D O I
10.1002/mds.22037
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The pharmacokinetics and pharmacodynamics of levodopa are dominated by two features: the Short plasma half-fife of the drug and the portion of the antiparkinsonian response that parallels the plasma levodopa levels. the so-called short-duration response. These features are the basis of Motor fluctuations that complicate long-term therapy with levodopa. Motor fluctuations will predictably improve with measures that prolong the elevations of plasma levodopa or prolong the efficacy of dopamine synthesized from exogenous levodopa. Because dyskinesia is closely linked to the short-duration response and conceivably part of the short-duration response, it is less clear that dyskinesia will be improved by therapeutic strategies that reduce motor fluctuations. (c) 2008 Movement Disorder Society.
引用
收藏
页码:S580 / S584
页数:5
相关论文
共 50 条
[21]   Application of Pharmacokinetics and Pharmacodynamics in Product Life Cycle Management. A Case Study with a Carbidopa-Levodopa Extended-Release Formulation [J].
Modi, Nishit B. .
AAPS JOURNAL, 2017, 19 (03) :607-618
[22]   Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease [J].
Ferreira, Joaquim J. ;
Poewe, Werner ;
Rascol, Olivier ;
Stocchi, Fabrizio ;
Antonini, Angelo ;
Moreira, Joana ;
Guimaraes, Bruno ;
Rocha, Jose-Francisco ;
Soares-da-Silva, Patricio .
MOVEMENT DISORDERS, 2022, 37 (11) :2272-2283
[23]   Effects of slowed gastrointestinal motility on levodopa pharmacokinetics [J].
Fernandez, Nelida ;
Garcia, Juan J. ;
Jose Diez, M. ;
Sahagun, Ana M. ;
Gonzalez, Aranzazu ;
Diez, Raquel ;
Sierra, Matilde .
AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL, 2010, 156 (1-2) :67-72
[24]   Effects of chronic levodopa therapy on dopa pharmacokinetics [J].
Murata, M ;
Kanazawa, I .
EUROPEAN NEUROLOGY, 1997, 38 :50-55
[25]   PHARMACOKINETICS OF CONTINUOUS-RELEASE CARBIDOPA/LEVODOPA [J].
SAGE, JI ;
MARK, MH .
CLINICAL NEUROPHARMACOLOGY, 1994, 17 :S1-S6
[26]   Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations [J].
Rocha, Jose-Francisco ;
Falcao, Amilcar ;
Santos, Ana ;
Pinto, Roberto ;
Lopes, Nelson ;
Nunes, Teresa ;
Wright, Lyndon C. ;
Vaz-da-Silva, Manuel ;
Soares-da-Silva, Patricio .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (09) :1059-1071
[27]   Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations [J].
José-Francisco Rocha ;
Amílcar Falcão ;
Ana Santos ;
Roberto Pinto ;
Nelson Lopes ;
Teresa Nunes ;
Lyndon C. Wright ;
Manuel Vaz-da-Silva ;
Patrício Soares-da-Silva .
European Journal of Clinical Pharmacology, 2014, 70 :1059-1071
[28]   Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules [J].
Modi, Nishit B. ;
Mittur, Aravind ;
Rubens, Robert ;
Khanna, Sarita ;
Gupta, Suneel .
CLINICAL NEUROPHARMACOLOGY, 2019, 42 (01) :4-8
[29]   Pharmacokinetics of levodopa/benserazide versus levodopa/carbidopa in healthy subjects and patients with Parkinson's disease [J].
Iwaki, Hirotaka ;
Nishikawa, Noriko ;
Nagai, Masahiro ;
Tsujii, Tomoaki ;
Yabe, Hayato ;
Kubo, Madoka ;
Ieiri, Ichiro ;
Nomoto, Masahiro .
NEUROLOGY AND CLINICAL NEUROSCIENCE, 2015, 3 (02) :68-73
[30]   Levodopa pharmacokinetics and dyskinesias: are there sex-related differences? [J].
Martinelli, P ;
Contin, M ;
Scaglione, C ;
Riva, R ;
Albani, F ;
Baruzzi, A .
NEUROLOGICAL SCIENCES, 2003, 24 (03) :192-193